SCHEMBL10028665

SCHEMBL10028665

CN(Cc1cccnc1)Cc1cccnc1

nearest known ligand 0.85

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.85
CHRNA4 P43681 3/20 0.85
CHRNA7 P36544 2/20 0.60
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
MAPK1 P28482 1/20 0.56
RIPK1 Q13546 1/20 0.53
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
OPRK1 P41145 1/20 0.51
OPRM1 P35372 1/20 0.51
OPRL1 P41146 1/20 0.51
LMNA P02545 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30093157 0.96 CHRNB2 (0.79) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL6674571 0.92 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL31044635 0.92 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL12195600 0.89 CHRNB2 (0.69) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL21278464 0.88 CHRNB2 (0.73) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL6132943 0.88 CHRNB2 (0.73) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL8348697 0.88 CHRNB2 (0.73) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL3239914 0.88 CHRNB2 (0.67) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL20609056 0.88 CHRNB2 (0.67) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1
SCHEMBL3460939 0.87 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9260663-B2 Liquid crystal composition, liquid crystal display, and method for producing liquid crystal display JSR CORPORATION (JP) 2016-02-16 US disclosed
US-9260663-B2 Liquid crystal composition, liquid crystal display, and method for producing liquid crystal display JSR CORPORATION (JP) 2016-02-16 US disclosed
US-20150092147-A1 LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY, AND METHOD FOR PRODUCING LIQUID CRYSTAL DISPLAY JSR CORPORATION (JP) 2015-04-02 US disclosed
US-20150092147-A1 LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY, AND METHOD FOR PRODUCING LIQUID CRYSTAL DISPLAY JSR CORPORATION (JP) 2015-04-02 US disclosed
US-8124720-B2 Triazine-based monomeric compound, di-triazine compound, and degradable polymer NATIONAL CHI NAN UNIVERSITY (TW) 2012-02-28 US disclosed
US-8124720-B2 Triazine-based monomeric compound, di-triazine compound, and degradable polymer NATIONAL CHI NAN UNIVERSITY (TW) 2012-02-28 US disclosed
US-20090312520-A1 Triazine-Based Monomeric Compound, Di-Triazine Compound, and Degradable Polymer NATIONAL CHI NAN UNIVERSITY (TW) 2009-12-17 US disclosed
US-20090312520-A1 Triazine-Based Monomeric Compound, Di-Triazine Compound, and Degradable Polymer NATIONAL CHI NAN UNIVERSITY (TW) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312520-A1 Triazine-Based Monomeric Compound, Di-Triazine Compound, and Degradable Polymer CCNB2, CCND2, CCNB1 CHRNB2 2638/4885CHRNA4 4091/4885CHRNA7 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.